ToolGen's 70 Billion KRW Rights Offering Dilutes Shareholders by 8.64% to Fund Patent Legal Battles and R&D Amid Persistent Losses and Cash Burn
ToolGen is issuing 777,000 common shares through a rights offering to raise approximately 70 billion KRW, diluting existing shareholders by about 8.64%.
About 37.5% of the proceeds (26.3 billion KRW) will be allocated to legal fees for US patent interference and CRISPR RNP infringement lawsuits, while 41.3% (29 billion KRW) is earmarked for R&D of key pipelines like GEB-200.
Major shareholder Genexine plans to subscribe only about 10% of its allocation, raising concerns over management stability; accumulated deficit of 170.5 billion KRW and persistent operating losses pressure the company for further capital.
The company has provided bank guarantees of approximately 3.17 billion KRW for foreign patent litigation, and prolonged litigation may increase legal costs beyond estimates.
[AI Summary]ToolGen's rights offering primarily aims to secure funds for R&D and patent disputes, but poses dilution and financial risks. Stock volatility may increase depending on litigation outcomes and pipeline progress.
KOSDAQ Filing Information
[Correction of Description] Securities Registration Statement (Equity Securities)